EP1567148A4 - Verfahren zur verwendung von undzusammensetzungen mit selektiven zytokin-hemmern zur behandlung undversorgung von makuladegeneration - Google Patents

Verfahren zur verwendung von undzusammensetzungen mit selektiven zytokin-hemmern zur behandlung undversorgung von makuladegeneration

Info

Publication number
EP1567148A4
EP1567148A4 EP03779423A EP03779423A EP1567148A4 EP 1567148 A4 EP1567148 A4 EP 1567148A4 EP 03779423 A EP03779423 A EP 03779423A EP 03779423 A EP03779423 A EP 03779423A EP 1567148 A4 EP1567148 A4 EP 1567148A4
Authority
EP
European Patent Office
Prior art keywords
compositions
management
treatment
methods
macular degeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03779423A
Other languages
English (en)
French (fr)
Other versions
EP1567148A2 (de
Inventor
Jerome B Zeldis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of EP1567148A2 publication Critical patent/EP1567148A2/de
Publication of EP1567148A4 publication Critical patent/EP1567148A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP03779423A 2002-10-31 2003-10-31 Verfahren zur verwendung von undzusammensetzungen mit selektiven zytokin-hemmern zur behandlung undversorgung von makuladegeneration Withdrawn EP1567148A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42290002P 2002-10-31 2002-10-31
US422900P 2002-10-31
PCT/US2003/034535 WO2004041181A2 (en) 2002-10-31 2003-10-31 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration

Publications (2)

Publication Number Publication Date
EP1567148A2 EP1567148A2 (de) 2005-08-31
EP1567148A4 true EP1567148A4 (de) 2010-09-15

Family

ID=32312567

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03779423A Withdrawn EP1567148A4 (de) 2002-10-31 2003-10-31 Verfahren zur verwendung von undzusammensetzungen mit selektiven zytokin-hemmern zur behandlung undversorgung von makuladegeneration

Country Status (12)

Country Link
EP (1) EP1567148A4 (de)
JP (1) JP2006509743A (de)
KR (1) KR20050062649A (de)
CN (1) CN1731997A (de)
AU (1) AU2003285107B2 (de)
BR (1) BR0315889A (de)
CA (1) CA2504263A1 (de)
MX (1) MXPA05004486A (de)
NZ (1) NZ540185A (de)
TW (1) TW200418455A (de)
WO (1) WO2004041181A2 (de)
ZA (1) ZA200503468B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
CN103402980B (zh) * 2011-01-10 2016-06-29 细胞基因公司 作为pde4和/或细胞因子抑制剂的苯乙基砜异吲哚啉衍生物
KR101908330B1 (ko) 2017-02-17 2018-10-16 인제대학교 산학협력단 신규 항-vegf 항체 및 이를 유효성분으로 포함하는 나이관련 황반변성 예방 또는 치료용 조성물
IL283127B1 (en) * 2018-11-14 2026-02-01 Smilebiotek Zhuhai Ltd Animal-based models, scanning methods, and methods of treating intraocular diseases or disorders
JP7443361B2 (ja) * 2018-12-03 2024-03-05 珠海岐微生物科技有限公司 加齢黄斑変性症の治療方法
JP7761924B2 (ja) * 2021-06-24 2025-10-29 山陽色素株式会社 赤色顔料分散体

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034606A1 (en) * 1999-11-12 2001-05-17 Celgene Corporation Pharmaceutically active isoindoline derivatives
WO2003088972A1 (en) * 2002-04-19 2003-10-30 Smithkline Beecham Corporation Novel compounds
WO2003097040A1 (en) * 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
WO2004034962A2 (en) * 2002-10-15 2004-04-29 Celgene Corporation Selective cytokine inhibitory drugs for treating myelodysplastic syndrome

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US577589A (en) * 1897-02-23 Valve for explosive-engines
US5605914A (en) * 1993-07-02 1997-02-25 Celgene Corporation Imides
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5770589A (en) * 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
JP2001511448A (ja) * 1997-07-31 2001-08-14 セルジーン コーポレイション 置換アルカノヒドロキサム酸およびＴＮＦαレベルの減少方法
AU749356B2 (en) * 1998-05-11 2002-06-27 Children's Medical Center Corporation Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
JP2000159761A (ja) * 1998-11-30 2000-06-13 Yoshio Takeuchi フルオロサリドマイド

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034606A1 (en) * 1999-11-12 2001-05-17 Celgene Corporation Pharmaceutically active isoindoline derivatives
WO2003088972A1 (en) * 2002-04-19 2003-10-30 Smithkline Beecham Corporation Novel compounds
WO2003097040A1 (en) * 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
WO2004034962A2 (en) * 2002-10-15 2004-04-29 Celgene Corporation Selective cytokine inhibitory drugs for treating myelodysplastic syndrome

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BULLETIN DE LA SOCIÉTÉ BELGE D'OPHTALMOLOGIE 1999 LNKD- PUBMED:10546384, vol. 273, 1999, pages 79 - 101, ISSN: 0081-0746 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1999, VEROUGSTRAETE C: "[Present and future treatment of age-related macular degeneration]", XP002590511, Database accession no. NLM10546384 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; May 2002 (2002-05-01), HATTENBACH LARS-OLOF ET AL: "Detection of inducible nitric oxide synthase and vascular endothelial growth factor in choroidal neovascular membranes.", XP002590512, Database accession no. NLM12065859 *
FEKRAT S ET AL: "THE EFFECT OF ORAL 13-CIS-RETINOIC ACID ON RETINAL REDETACHMENT AFTER SURGICAL REPAIR IN EYES WITH PROLIFERATIVE VITREORETINOPATHY", OPHTHALMOLOGY, J. B. LIPPINCOTT CO., PHILADELPHIA, PA, US, vol. 102, no. 3, 1 March 1995 (1995-03-01), pages 412 - 418, XP000942676, ISSN: 0161-6420 *
MILLER D W ET AL.: "[The molecular mechanisms of neovascular age-related macular degeneration]", DER OPHTHALMOLOGE : ZEITSCHRIFT DER DEUTSCHEN OPHTHALMOLOGISCHEN GESELLSCHAFT FEB 2003 LNKD- PUBMED:12589451, vol. 100, no. 2, February 2003 (2003-02-01), pages 92 - 96, XP002590513, ISSN: 0941-293X *
RADU ROXANA A ET AL: "Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 15 APR 2003 LNKD- PUBMED:12671074, vol. 100, no. 8, 15 April 2003 (2003-04-15), pages 4742 - 4747, XP002590514, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
ZA200503468B (en) 2006-10-25
CA2504263A1 (en) 2004-05-21
TW200418455A (en) 2004-10-01
NZ540185A (en) 2008-01-31
MXPA05004486A (es) 2005-07-26
EP1567148A2 (de) 2005-08-31
WO2004041181A3 (en) 2005-02-17
WO2004041181A2 (en) 2004-05-21
KR20050062649A (ko) 2005-06-23
BR0315889A (pt) 2005-10-04
CN1731997A (zh) 2006-02-08
AU2003285107B2 (en) 2008-01-10
JP2006509743A (ja) 2006-03-23
AU2003285107A1 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
IL165258A0 (en) Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
IL175074A0 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatement, modification and management of pain
IL163831A (en) Derivatives of aminoindazoles, pharmaceutical compositions comprising them, process for their preparation and use thereof
EP1567154A4 (de) Verfahren undzusammensetzungen mit selektiven cytokin-hemmenden arzneimitteln zurbehandlung und versorgung von krebs und anderen erkrankungen
EP1567157A4 (de) Verfahren zur verwendung und zusammensetzungen, umfassend immunomodulatorische verbindungen für die therapie und behandlung von knochenmarkbildungskrankheiten
EP1696910A4 (de) Zusammensetzungen und verfahren zur behandlung von fibrose
EP1699431A4 (de) Zusammensetzungen zur behandlung von ohrerkrankungen und anwendungsverfahren
ZA200503241B (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
IL162765A (en) Diazabicycle derivatives, processes for their preparation, pharmaceutical compositions comprising them and their medical use
PT1478339E (pt) Formulações farmacêuticas de agentes antineoplásticos, em particular temozolomida, processos para a sua produção e utilização
IL174627A0 (en) Compositions and methods for treatment of burns
EP1534295A4 (de) Formulierungen und verfahren zur verabreichung von cephalotaxinen, einschliesslich homoharringtonin
AU2003234545A8 (en) Pharmaceutical compositions and methods of using c-21 modified epothilone derivatives
AU2003295473A1 (en) Method of preparing anti-angiogenic drug from cartillage and chondrocytes and methods of use
EP1562597A4 (de) Anwendungsverfahren für und zusammensetzungen mit immunomodulatorischen verbindungen zur behandlung und versorgung von makuladegeneration
EP1605935A4 (de) Verfahren zur verwendung von und zusammensetzungen mit selektiven zyotkin-hemmenden arzneimitteln zur behandlung und versorgung von erkrankungen des zentralen nervensystems
IL179038A0 (en) Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
PT1667693E (pt) Composições e métodos para usar corpos lamelares com fins terapêuticos
EP1569903A4 (de) Verfahren zur anwendung von selektivencytokinhemmenden arzneimitteln zur behandlung und betreuung von myeloproliferativenkrankheiten und zusammensetzungen, die diese arzneimittel enthalten
EP1744748A4 (de) Verfahren zur verwendung von selektiven zytokin-hemmenden arzneimitteln und diese enthaltende zusammensetzungen zur behandlung und versorgung von myelodysplastischen syndromen
GB0324523D0 (en) Compositions and methods of treatment
IL166062A0 (en) Compositions and methods for therapeutic treatment
ZA200607641B (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
IL175311A0 (en) Cytokine inhibitory drugs for treatment of macular degeneration
EP1569723A4 (de) Arzneimittel auf nukleotidgrundlage undverfahren zu seiner verwendung für die behandlung von krankheiten desmenschen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050530

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CELGENE CORPORATION

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 27/02 20060101ALI20100805BHEP

Ipc: A61K 31/4035 20060101ALI20100805BHEP

Ipc: A61K 31/00 20060101ALI20100805BHEP

Ipc: A61K 31/40 20060101AFI20050228BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100813

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101111